{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:05:39Z","timestamp":1790870739609,"version":"4.1.0"},"reference-count":166,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015550","name":"European Union\u2014NextGenerationEU\u2014PNRR M6C2\u2014Investment 2.1 Valorizzazione e potenziamento della ricerca biomedica del SSN\u2014Italian Ministry of Health","doi-asserted-by":"publisher","award":["PNRR-MCNT1-2023-12377835"],"award-info":[{"award-number":["PNRR-MCNT1-2023-12377835"]}],"id":[{"id":"10.13039\/501100015550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Multiple myeloma (MM) is a genetically and clinically heterogeneous plasma cell malignancy characterised by clonal expansion of differentiated B cells within the bone marrow (BM). Patients start with monoclonal gammopathy of undetermined significance (MGUS) and progress to an intermediate stage called smouldering multiple myeloma (SMM), characterised by several genetic alterations that represent the genomic backbone of the malignant clone. Immune checkpoint pathways play a central role in shaping an immunosuppressive BM niche, contributing to T-cell dysfunction, immune evasion, and therapeutic resistance. Key inhibitory receptors such as PD-1, CTLA-4, TIM-3, LAG-3, and CD47 are frequently dysregulated, promoting T-cell exhaustion, anergy, and senescence. Emerging evidence highlights extracellular vesicles (EVs) as critical mediators of intercellular communication in MM. MM-derived EVs carry bioactive cargo, including proteins and miRNAs, that reprogram immune and stromal cells, enhancing tumour progression and immune escape. Notably, EV-associated immune checkpoint molecules contribute to the establishment of a permissive microenvironment. This review provides an integrated overview of immune checkpoint dysregulation and EV-mediated immunomodulation in MM, emphasising their role in disease pathogenesis and progression. Furthermore, we discuss the therapeutic potential of targeting immune checkpoints and exploiting EVs as novel biomarkers and drug delivery systems, highlighting their promise for improving precision medicine approaches in MM.<\/jats:p>","DOI":"10.3390\/ijms27146276","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:06:52Z","timestamp":1784084812000},"page":"6276","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Extracellular Vesicles as Master Regulators of Immune Modulation in Multiple Myeloma"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0905-1958","authenticated-orcid":false,"given":"Marzia","family":"Pucci","sequence":"first","affiliation":[{"name":"Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Via Divisi 83, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1637-1797","authenticated-orcid":false,"given":"Elisa","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Via Divisi 83, 90133 Palermo, Italy"},{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9032-6210","authenticated-orcid":false,"given":"Martina","family":"Marfia","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Via Divisi 83, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Seidita","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Via Divisi 83, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4681-2170","authenticated-orcid":false,"given":"Simona","family":"Fontana","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Via Divisi 83, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-0793","authenticated-orcid":false,"given":"Chiara","family":"Corrado","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Via Divisi 83, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9935-1040","authenticated-orcid":false,"given":"Riccardo","family":"Alessandro","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Via Divisi 83, 90133 Palermo, Italy"},{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple Myeloma","volume":"397","author":"Pawlyn","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e70067","DOI":"10.1002\/hon.70067","article-title":"Multiple Myeloma Unpacked","volume":"43","author":"Gay","year":"2025","journal-title":"Hematol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101168","DOI":"10.1016\/j.blre.2024.101168","article-title":"Chromosomal Defects in Multiple Myeloma","volume":"64","author":"Clarke","year":"2024","journal-title":"Blood Rev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Barwick, B.G., Gupta, V.A., Vertino, P.M., and Boise, L.H. (2019). Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01121"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma","volume":"43","author":"Davies","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN Evidence-Based Guidelines for Diagnosis, Treatment and Follow-up of Patients with Multiple Myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.hoc.2023.12.010","article-title":"Molecular Pathogenesis of Multiple Myeloma: Clinical Implications","volume":"38","author":"Maura","year":"2024","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/oncsis.2017.36","article-title":"Molecular Signaling in Multiple Myeloma: Association of RAS\/RAF Mutations and MEK\/ERK Pathway Activation","volume":"6","author":"Xu","year":"2017","journal-title":"Oncogenesis"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12032-025-02807-0","article-title":"Genetic, Epigenetic, and Molecular Determinants of Multiple Myeloma and Precursor Plasma Cell Disorders: A Pathophysiological Overview","volume":"42","author":"Sutanto","year":"2025","journal-title":"Med. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"157496","DOI":"10.1155\/2012\/157496","article-title":"Bone Marrow Microenvironment in Multiple Myeloma Progression","volume":"2012","author":"Manier","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lopes, R., Caetano, J., Ferreira, B., Barahona, F., Carneiro, E.A., and Jo\u00e3o, C. (2021). The Immune Microenvironment in Multiple Myeloma: Friend or Foe?. Cancers, 13.","DOI":"10.3390\/cancers13040625"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"117503","DOI":"10.1016\/j.lfs.2020.117503","article-title":"IGF-1 Promotes Multiple Myeloma Progression through PI3K\/Akt-Mediated Epithelial-Mesenchymal Transition","volume":"249","author":"Peng","year":"2020","journal-title":"Life Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"29061","DOI":"10.1038\/s41598-024-76465-z","article-title":"The MAPK\/ERK Signaling Pathway Involved in Raddeanin A Induces Apoptosis via the Mitochondrial Pathway and G2 Phase Arrest in Multiple Myeloma","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Bergiers, I., K\u00f6se, M.C., Skerget, S., Malfait, M., Fourneau, N., Ellis, J.-C., Vanhoof, G., Smets, T., Verbist, B., and De Maeyer, D. (2025). Immunophenotypic Changes in the Tumor and Tumor Microenvironment during Progression to Multiple Myeloma. PLoS Genet., 21.","DOI":"10.1371\/journal.pgen.1011848"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","article-title":"Comprehensive Molecular Profiling of Multiple Myeloma Identifies Refined Copy Number and Expression Subtypes","volume":"56","author":"Skerget","year":"2024","journal-title":"Nat. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","article-title":"Multiple Myeloma: Signaling Pathways and Targeted Therapy","volume":"5","author":"Lu","year":"2024","journal-title":"Mol. Biomed."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of Multiple Myeloma-Related Renal Impairment: Recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The Epidemiological Landscape of Multiple Myeloma: A Global Cancer Registry Estimate of Disease Burden, Risk Factors, and Temporal Trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/ejh.12478","article-title":"Clinical Course and Prognosis of Non-Secretory Multiple Myeloma","volume":"95","author":"Chawla","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for Multiple Myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group Risk Stratification Model for Smoldering Multiple Myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin. Proc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project","volume":"40","author":"Cairns","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A Simple Additive Staging System for Newly Diagnosed Multiple Myeloma","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The Multiple Myelomas\u2014Current Concepts in Cytogenetic Classification and Therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/hematology.2023000443","article-title":"A Rational Approach to Functional High-Risk Myeloma","volume":"2023","author":"Gay","year":"2023","journal-title":"Hematology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2022.07.030","article-title":"Lenalidomide-Dexamethasone versus Observation in High-Risk Smoldering Myeloma after 12 Years of Median Follow-up Time: A Randomized, Open-Label Study","volume":"174","author":"Mateos","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1182\/blood.V128.22.976.976","article-title":"Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma","volume":"128","author":"Ghobrial","year":"2016","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2021-149787","article-title":"A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma","volume":"138","author":"Nadeem","year":"2021","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood-2023-181811","article-title":"Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial","volume":"142","author":"Hill","year":"2023","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","article-title":"Phase 1 Study of CART-ddBCMA for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma","volume":"7","author":"Frigault","year":"2023","journal-title":"Blood Adv."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Costa, F., Das, R., Kini Bailur, J., Dhodapkar, K., and Dhodapkar, M.V. (2018). Checkpoint Inhibition in Myeloma: Opportunities and Challenges. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02204"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.2024025897","article-title":"Efficacy and Safety of Daratumumab in Intermediate\/High-Risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS","volume":"145","author":"Landgren","year":"2025","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1200\/OP-24-00752","article-title":"Novel Treatment Options for Multiple Myeloma","volume":"21","author":"Portuguese","year":"2025","journal-title":"JCO Oncol. Pract."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Sutanto, H., Romadhon, P.Z., Fatmawati, V.R., Waitupu, A., Ansharullah, B.A., Rachma, B., Elisa, E., Pratiwi, L., and Adytia, G.J. (2025). Multiple Myeloma and Precursor Plasma Cell Disorders: From Emerging Driver Mutations to Current and Future Therapeutic Strategies. Hemato, 6.","DOI":"10.3390\/hemato6030029"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101177","DOI":"10.1016\/j.neo.2025.101177","article-title":"MYC Alterations in Multiple Myeloma: Genetic Insights and Prognostic Impact","volume":"66","author":"Cuadrado","year":"2025","journal-title":"Neoplasia"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Fotiou, D., and Katodritou, E. (2025). From Biology to Clinical Practice: The Bone Marrow Microenvironment in Multiple Myeloma. J. Clin. Med., 14.","DOI":"10.3390\/jcm14020327"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"101189","DOI":"10.1016\/j.neo.2025.101189","article-title":"Single-Cell Proteomic Analysis Reveals Multiple Myeloma Heterogeneity and the Dynamics of the Tumor Immune Microenvironment in Precursor and Advanced States","volume":"66","author":"Kamal","year":"2025","journal-title":"Neoplasia"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Desantis, V., Savino, F.D., Scaringella, A., Potenza, M.A., Nacci, C., Frassanito, M.A., Vacca, A., and Montagnani, M. (2022). The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092513"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"15662","DOI":"10.1038\/s41598-025-00074-7","article-title":"Bioinformatics Analysis of Intrinsic Drivers of Immune Dysregulation in Multiple Myeloma to Elucidate Immune Phenotypes and Discover Prognostic Gene Signatures","volume":"15","author":"Fang","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41408-024-01172-x","article-title":"Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages","volume":"14","author":"Cheng","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2542333","DOI":"10.1080\/2162402X.2025.2542333","article-title":"CyTOF Profiling of Bone Marrow Immune Dynamics across Myeloma Stages","volume":"14","author":"Cholujova","year":"2025","journal-title":"Oncoimmunology"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Luoma, S., Sergeev, P., Javarappa, K.K., \u00d6hman, T.J., Varjosalo, M., S\u00e4ily, M., Anttila, P., Sankelo, M., Partanen, A., and Nihtinen, A. (2023). Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy. Cancers, 15.","DOI":"10.3390\/cancers15092604"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Zhao, Z., Zhao, Z., Lin, Z., Fan, L., Xiahou, Z., Dong, Y., and Bao, W. (2025). Decoding Multiple Myeloma: Single-Cell Insights into Tumor Heterogeneity, Immune Dynamics, and Disease Progression. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1584350"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1038\/s41467-023-41562-6","article-title":"Large T Cell Clones Expressing Immune Checkpoints Increase during Multiple Myeloma Evolution and Predict Treatment Resistance","volume":"14","author":"Botta","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/BLCTT.S517354","article-title":"A Monocyte-Driven Prognostic Model for Multiple Myeloma: Multi-Omics and Machine Learning Insights","volume":"15","author":"Xie","year":"2025","journal-title":"Blood Lymphat. Cancer Targets Ther."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ye, C., Chen, X., Chen, Z., Liu, S., Kong, R., Lin, W., Zhu, M., Sun, X., and Xu, Z. (2025). Comprehensive Analysis of Single-Cell and Bulk RNA Sequencing Data Reveals an EGFR Signature for Predicting Immunotherapy Response and Prognosis in Pan-Cancer. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1604394"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cytogfr.2016.02.004","article-title":"CD28 Costimulatory Signals in T Lymphocyte Activation: Emerging Functions beyond a Qualitative and Quantitative Support to TCR Signalling","volume":"28","author":"Porciello","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T Cells in Multiple Myeloma Display Features of Exhaustion and Senescence at the Tumor Site","volume":"9","author":"Thangavadivel","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple Myeloma Causes Clonal T-Cell Immunosenescence: Identification of Potential Novel Targets for Promoting Tumour Immunity and Implications for Checkpoint Blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41586-025-09539-1","article-title":"Proteotoxic Stress Response Drives T Cell Exhaustion and Immune Evasion","volume":"647","author":"Wang","year":"2025","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","article-title":"Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment","volume":"30","author":"Ma","year":"2019","journal-title":"Cell Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma Cells from Multiple Myeloma Patients Express B7-H1 (PD-L1) and Increase Expression after Stimulation with IFN-{gamma} and TLR Ligands via a MyD88-, TRAF6-, and MEK-Dependent Pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ccell.2018.02.005","article-title":"Tumor-Repopulating Cells Induce PD-1 Expression in CD8+ T Cells by Transferring Kynurenine and AhR Activation","volume":"33","author":"Liu","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Lv, J., Sun, H., Gong, L., Wei, X., He, Y., Yu, Z., Liu, L., Yi, S., Sui, W., and Xu, Y. (2022). Aberrant Metabolic Processes Promote the Immunosuppressive Microenvironment in Multiple Myeloma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1077768"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Huang, S., Zhao, Y., Liao, P., Wang, J., Li, Z., Tan, J., Zha, X., Chen, S., Li, Y., and Zhong, L. (2022). Different Expression Patterns of VISTA Concurrent with PD-1, Tim-3, and TIGIT on T Cell Subsets in Peripheral Blood and Bone Marrow from Patients with Multiple Myeloma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1014904"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1038\/s41467-019-11280-z","article-title":"Regulation of Antitumour CD8 T-Cell Immunity and Checkpoint Blockade Immunotherapy by Neuropilin-1","volume":"10","author":"Leclerc","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e157907","DOI":"10.1172\/JCI157907","article-title":"TIGIT Inhibition and Lenalidomide Synergistically Promote Antimyeloma Immune Responses after Stem Cell Transplantation in Mice","volume":"133","author":"Minnie","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune Checkpoint Therapy-Current Perspectives and Future Directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/leu.2013.310","article-title":"Coinhibitory Molecule PD-1 as a Potential Target for the Immunotherapy of Multiple Myeloma","volume":"28","author":"Atanackovic","year":"2014","journal-title":"Leukemia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and Its Ligands in Tolerance and Immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","article-title":"Immune Checkpoint Blockade in Hematologic Malignancies","volume":"125","author":"Armand","year":"2015","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Kulikowska de Na\u0142\u0119cz, A., Ciszak, L., Usnarska-Zubkiewicz, L., Pawlak, E., Frydecka, I., Szmyrka, M., and Kosmaczewska, A. (2023). Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065730"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma","volume":"21","author":"Samur","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CJI.0b013e31821ca6ce","article-title":"PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-Cell Responses to Autologous Dendritic Cell\/Myeloma Fusion Vaccine","volume":"34","author":"Rosenblatt","year":"2011","journal-title":"J. Immunother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2015-03-632919","article-title":"Prospective Analysis of Antigen-Specific Immunity, Stem-Cell Antigens, and Immune Checkpoints in Monoclonal Gammopathy","volume":"126","author":"Dhodapkar","year":"2015","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.blre.2016.04.002","article-title":"Myeloid-Derived Suppressor Cells: The Green Light for Myeloma Immune Escape","volume":"30","author":"Malek","year":"2016","journal-title":"Blood Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.0105-2896.2010.00903.x","article-title":"TIM Genes: A Family of Cell Surface Phosphatidylserine Receptors That Regulate Innate and Adaptive Immunity","volume":"235","author":"Freeman","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Legat, A., Speiser, D.E., Pircher, H., Zehn, D., and Fuertes Marraco, S.A. (2013). Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than \u201cExhaustion\u201d of Human CD8\u2009T Cells. Front. Immunol., 4.","DOI":"10.3389\/fimmu.2013.00455"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e23849","DOI":"10.4161\/onci.23849","article-title":"TIM3+FOXP3+ Regulatory T Cells Are Tissue-Specific Promoters of T-Cell Dysfunction in Cancer","volume":"2","author":"Sakuishi","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1126\/science.1148536","article-title":"Promotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune Cells","volume":"318","author":"Anderson","year":"2007","journal-title":"Science"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","article-title":"Tim-3 Marks Human Natural Killer Cell Maturation and Suppresses Cell-Mediated Cytotoxicity","volume":"119","author":"Ndhlovu","year":"2012","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.it.2011.05.003","article-title":"Emerging Tim-3 Functions in Antimicrobial and Tumor Immunity","volume":"32","author":"Sakuishi","year":"2011","journal-title":"Trends Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-Infiltrating DCs Suppress Nucleic Acid-Mediated Innate Immune Responses through Interactions between the Receptor TIM-3 and the Alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1111\/ajco.13033","article-title":"Increased Exhausted CD8+ T Cells with Programmed Death-1, T-Cell Immunoglobulin and Mucin-Domain-Containing-3 Phenotype in Patients with Multiple Myeloma","volume":"14","author":"Tan","year":"2018","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Liu, Z., Xiang, C., Han, M., Meng, N., Luo, J., and Fu, R. (2020). Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation via NF-\u03baB Signal Pathways. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.584530"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4149\/neo_2025_251026N448","article-title":"Immune Checkpoint Remodeling across Disease Progression in Multiple Myeloma","volume":"73","author":"Valuskova","year":"2026","journal-title":"Neoplasma"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Alibrahim, M.N., Carbone, A., Alsaleh, N., and Gloghini, A. (2025). Immune Checkpoint Molecules in Hodgkin Lymphoma and Other Hematological Malignancies. Cancers, 17.","DOI":"10.3390\/cancers17142292"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e000482","DOI":"10.1136\/esmoopen-2018-000482","article-title":"New Emerging Targets in Cancer Immunotherapy: The Role of LAG3","volume":"4","author":"Puhr","year":"2019","journal-title":"ESMO Open"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bbmt.2019.08.009","article-title":"T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma","volume":"26","author":"Lucas","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s40001-022-00923-5","article-title":"PD-1 and LAG-3-Positive T Cells Are Associated with Clinical Outcomes of Relapsed\/Refractory Multiple Myeloma Patients","volume":"27","author":"Chen","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/leu.2012.141","article-title":"Anti-CD47 Antibodies Promote Phagocytosis and Inhibit the Growth of Human Myeloma Cells","volume":"26","author":"Kim","year":"2012","journal-title":"Leukemia"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Sun, J., Muz, B., Alhallak, K., Markovic, M., Gurley, S., Wang, Z., Guenthner, N., Wasden, K., Fiala, M., and King, J. (2020). Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12020305"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e12404","DOI":"10.1002\/jev2.12404","article-title":"Minimal Information for Studies of Extracellular Vesicles (MISEV2023): From Basic to Advanced Approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Ahn, M., Mun, J.-G., Han, Y., and Seo, J.H. (2025). Cancer Cell-Derived Extracellular Vesicles: A Potential Target for Overcoming Tumor Immunotherapy Resistance and Immune Evasion Strategies. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1601266"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/blood-2014-05-576116","article-title":"Exosomal miR-135b Shed from Hypoxic Multiple Myeloma Cells Enhances Angiogenesis by Targeting Factor-Inhibiting HIF-1","volume":"124","author":"Umezu","year":"2014","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1038\/s41388-019-0788-4","article-title":"piRNA-823 Delivered by Multiple Myeloma-Derived Extracellular Vesicles Promoted Tumorigenesis through Re-Educating Endothelial Cells in the Tumor Environment","volume":"38","author":"Li","year":"2019","journal-title":"Oncogene"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10456-018-9649-y","article-title":"Extracellular Vesicles of Multiple Myeloma Cells Utilize the Proteasome Inhibitor Mechanism to Moderate Endothelial Angiogenesis","volume":"22","author":"Zarfati","year":"2019","journal-title":"Angiogenesis"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41408-018-0139-7","article-title":"Exosomes Play a Role in Multiple Myeloma Bone Disease and Tumor Development by Targeting Osteoclasts and Osteoblasts","volume":"8","author":"Faict","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13045-018-0689-y","article-title":"Multiple Myeloma-Derived Exosomes Are Enriched of Amphiregulin (AREG) and Activate the Epidermal Growth Factor Pathway in the Bone Microenvironment Leading to Osteoclastogenesis","volume":"12","author":"Raimondo","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"13772","DOI":"10.18632\/oncotarget.3830","article-title":"Involvement of Multiple Myeloma Cell-Derived Exosomes in Osteoclast Differentiation","volume":"6","author":"Raimondi","year":"2015","journal-title":"Oncotarget"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Raimondo, S., Urz\u00ec, O., Conigliaro, A., Bosco, G.L., Parisi, S., Carlisi, M., Siragusa, S., Raimondi, L., Luca, A.D., and Giavaresi, G. (2020). Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12020449"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2014-03-562439","article-title":"Bone Marrow Stromal Cell-Derived Exosomes as Communicators in Drug Resistance in Multiple Myeloma Cells","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/path.5852","article-title":"Myeloma Cells Regulate miRNA Transfer from Fibroblast-Derived Exosomes by Expression of lncRNAs","volume":"256","author":"Saltarella","year":"2022","journal-title":"J. Pathol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"43992","DOI":"10.18632\/oncotarget.6083","article-title":"The Bone Marrow Microenvironment Enhances Multiple Myeloma Progression by Exosome-Mediated Activation of Myeloid-Derived Suppressor Cells","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/path.4712","article-title":"Multiple Myeloma Exosomes Establish a Favourable Bone Marrow Microenvironment with Enhanced Angiogenesis and Immunosuppression","volume":"239","author":"Wang","year":"2016","journal-title":"J. Pathol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e129348","DOI":"10.1172\/jci.insight.129348","article-title":"MiR-16 Regulates Crosstalk in NF-\u03baB Tolerogenic Inflammatory Signaling between Myeloma Cells and Bone Marrow Macrophages","volume":"4","author":"Khalife","year":"2019","journal-title":"JCI Insight"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Saltarella, I., Lamanuzzi, A., Apollonio, B., Desantis, V., Bartoli, G., Vacca, A., and Frassanito, M.A. (2021). Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression. Cells, 10.","DOI":"10.3390\/cells10113185"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.semcancer.2007.07.004","article-title":"Soluble HLA-G: Are They Clinically Relevant?","volume":"17","author":"Pistoia","year":"2007","journal-title":"Semin. Cancer Biol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Li, P., Wang, N., Zhang, Y., Wang, C., and Du, L. (2021). HLA-G\/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.791535"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1158\/1078-0432.CCR-05-0456","article-title":"Total Soluble HLA Class I and Soluble HLA-G in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance","volume":"11","author":"Leleu","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2012-03-416792","article-title":"CD86+ or HLA-G+ Can Be Transferred via Trogocytosis from Myeloma Cells to T Cells and Are Associated with Poor Prognosis","volume":"120","author":"Brown","year":"2012","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Soncini, D., Marimpietri, D., Ladisa, F., Lai, F., Airoldi, I., Gramignoli, R., Cea, M., and Morandi, F. (2025). Bone Marrow-Derived Extracellular Vesicles from Multiple Myeloma Patients Promote Adaptive Immune Dysfunction via HLA-G, PD-1, and PD-L1. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1640168"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 Contributes to Immunosuppression and Is Associated with Anti-PD-1 Response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1245\/s10434-019-07431-7","article-title":"Exosomal PD-L1 Retains Immunosuppressive Activity and Is Associated with Gastric Cancer Prognosis","volume":"26","author":"Fan","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"114519","DOI":"10.1016\/j.intimp.2025.114519","article-title":"Exosomal PD-L1 in Non-Small Cell Lung Cancer: Implications for Immune Evasion and Resistance to Immunotherapy","volume":"155","author":"Tarin","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","article-title":"Suppression of Exosomal PD-L1 Induces Systemic Anti-Tumor Immunity and Memory","volume":"177","author":"Poggio","year":"2019","journal-title":"Cell"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/carcin\/bgz124","article-title":"Tumor-Derived Exosomes Promote Carcinogenesis of Murine Oral Squamous Cell Carcinoma","volume":"41","author":"Razzo","year":"2020","journal-title":"Carcinogenesis"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"eaar2766","DOI":"10.1126\/sciadv.aar2766","article-title":"Immune Evasion Mediated by PD-L1 on Glioblastoma-Derived Extracellular Vesicles","volume":"4","author":"Ricklefs","year":"2018","journal-title":"Sci. Adv."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/1078-0432.CCR-17-2664","article-title":"Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients","volume":"24","author":"Theodoraki","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41422-018-0060-4","article-title":"Exosomal PD-L1 Harbors Active Defense Function to Suppress T Cell Killing of Breast Cancer Cells and Promote Tumor Growth","volume":"28","author":"Yang","year":"2018","journal-title":"Cell Res."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Pucci, M., Raimondo, S., Urz\u00ec, O., Moschetti, M., Di Bella, M.A., Conigliaro, A., Caccamo, N., La Manna, M.P., Fontana, S., and Alessandro, R. (2021). Tumor-Derived Small Extracellular Vesicles Induce Pro-Inflammatory Cytokine Expression and PD-L1 Regulation in M0 Macrophages via IL-6\/STAT3 and TLR4 Signaling Pathways. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212118"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/cas.70099","article-title":"Immunosuppressive Effects of Multiple Myeloma-Derived Extracellular Vesicles Through T Cell Exhaustion","volume":"116","author":"Hagiwara","year":"2025","journal-title":"Cancer Sci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncb1596","article-title":"Exosome-Mediated Transfer of mRNAs and microRNAs Is a Novel Mechanism of Genetic Exchange between Cells","volume":"9","author":"Valadi","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Yamamoto, T., Kosaka, N., Hattori, Y., and Ochiya, T. (2018). A Challenge to Aging Society by microRNA in Extracellular Vesicles: microRNA in Extracellular Vesicles as Promising Biomarkers and Novel Therapeutic Targets in Multiple Myeloma. J. Clin. Med., 7.","DOI":"10.3390\/jcm7030055"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e70036","DOI":"10.1002\/hon.70036","article-title":"MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia","volume":"43","author":"Gregorova","year":"2025","journal-title":"Hematol. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.canlet.2016.04.024","article-title":"Induction of miR-146a by Multiple Myeloma Cells in Mesenchymal Stromal Cells Stimulates Their pro-Tumoral Activity","volume":"377","author":"Wang","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/bjh.19049","article-title":"Tumour-Derived Exosomes Promote the Induction of Monocytic Myeloid-Derived Suppressor Cells from Peripheral Blood Mononuclear Cells by Delivering miR-106a-5p and miR-146a-5p in Multiple Myeloma","volume":"203","author":"Mizuhara","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Mielnik, M., Szudy-Szczyrek, A., Homa-Mlak, I., Mlak, R., Podgajna-Mielnik, M., Gor\u0105cy, A., Ma\u0142ecka-Massalska, T., and Hus, M. (2023). The Clinical Relevance of Selected Cytokines in Newly Diagnosed Multiple Myeloma Patients. Biomedicines, 11.","DOI":"10.3390\/biomedicines11113012"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Leone, P., Solimando, A.G., Malerba, E., Fasano, R., Buonavoglia, A., Pappagallo, F., De Re, V., Argentiero, A., Silvestris, N., and Vacca, A. (2020). Actors on the Scene: Immune Cells in the Myeloma Niche. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.599098"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Iannozzi, N.T., Giuliani, N., and Storti, P. (2025). Deciphering the Bone Marrow Microenvironment\u2019s Role in Multiple Myeloma Immunotherapy Resistance. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1613265"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2018.11.002","article-title":"Myeloid-Derived Suppressor Cells Induce Multiple Myeloma Cell Survival by Activating the AMPK Pathway","volume":"442","author":"Menu","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/blood-2008-08-173914","article-title":"ATM-ATR-Dependent up-Regulation of DNAM-1 and NKG2D Ligands on Multiple Myeloma Cells by Therapeutic Agents Results in Enhanced NK-Cell Susceptibility and Is Associated with a Senescent Phenotype","volume":"113","author":"Soriani","year":"2009","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.7150\/jca.55553","article-title":"Exosomal miR-1305 in the Oncogenic Activity of Hypoxic Multiple Myeloma Cells: A Biomarker for Predicting Prognosis","volume":"12","author":"Lee","year":"2021","journal-title":"J. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Zingoni, A., Vulpis, E., Cecere, F., Amendola, M.G., Fuerst, D., Saribekyan, T., Achour, A., Sandalova, T., Nardone, I., and Peri, A. (2018). MICA-129 Dimorphism and Soluble MICA Are Associated with the Progression of Multiple Myeloma. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00926"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Lopes, R., Caetano, J., Barahona, F., Pestana, C., Ferreira, B.V., Louren\u00e7o, D., Queir\u00f3s, A.C., Bilreiro, C., Shemesh, N., and Beck, H.C. (2022). Multiple Myeloma-Derived Extracellular Vesicles Modulate the Bone Marrow Immune Microenvironment. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.909880"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/sji.12072","article-title":"Generation of Soluble NKG2D Ligands: Proteolytic Cleavage, Exosome Secretion and Functional Implications","volume":"78","author":"Chitadze","year":"2013","journal-title":"Scand. J. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e12176","DOI":"10.1002\/jev2.12176","article-title":"Impact on NK Cell Functions of Acute versus Chronic Exposure to Extracellular Vesicle-Associated MICA: Dual Role in Cancer Immunosurveillance","volume":"11","author":"Vulpis","year":"2022","journal-title":"J. Extracell. Vesicles"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/apm.13306","article-title":"Multiple Myeloma Cell-Derived Exosomes Promote Favorable Tumor Functional Performance by Polarizing Macrophages toward M2-like Cells","volume":"131","author":"Razi","year":"2023","journal-title":"APMIS Acta Pathol. Microbiol. Immunol. Scand."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Sheridan, R., Brennan, K., Bazou, D., O\u2019Gorman, P., Matallanas, D., and Mc Gee, M.M. (2024). Multiple Myeloma Derived Extracellular Vesicle Uptake by Monocyte Cells Stimulates IL-6 and MMP-9 Secretion and Promotes Cancer Cell Migration and Proliferation. Cancers, 16.","DOI":"10.3390\/cancers16051011"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Iskrzak, J., Zygmunciak, P., Misiewicz-Krzemi\u0144ska, I., and Pu\u0142a, B. (2022). Extracellular Vesicles in Multiple Myeloma-Cracking the Code to a Better Understanding of the Disease. Cancers, 14.","DOI":"10.3390\/cancers14225575"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"60698","DOI":"10.18632\/oncotarget.10849","article-title":"Microenvironment Drug Resistance in Multiple Myeloma: Emerging New Players","volume":"7","author":"Desantis","year":"2016","journal-title":"Oncotarget"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/jim-2019-001010","article-title":"Multiple Myeloma-Derived Exosomes Inhibit Osteoblastic Differentiation and Improve IL-6 Secretion of BMSCs from Multiple Myeloma","volume":"68","author":"Liu","year":"2020","journal-title":"J. Investig. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e2000119","DOI":"10.1002\/pmic.202000119","article-title":"Human Myeloma Cell- and Plasma-Derived Extracellular Vesicles Contribute to Functional Regulation of Stromal Cells","volume":"21","author":"Reale","year":"2021","journal-title":"Proteomics"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3109\/10428194.2011.591004","article-title":"Myeloma Cell Adhesion to Bone Marrow Stromal Cells Confers Drug Resistance by microRNA-21 up-Regulation","volume":"52","author":"Wang","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","article-title":"Multiple Myeloma Cell Adhesion-Induced Interleukin-6 Expression in Bone Marrow Stromal Cells Involves Activation of NF-Kappa B","volume":"87","author":"Chauhan","year":"1996","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Cippitelli, M., Stabile, H., Kosta, A., Petillo, S., Lucantonio, L., Gismondi, A., Santoni, A., and Fionda, C. (2023). Role of NF-\u03baB Signaling in the Interplay between Multiple Myeloma and Mesenchymal Stromal Cells. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24031823"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts Enhance Myeloma Cell Growth and Survival via Cell-Cell Contact: A Vicious Cycle between Bone Destruction and Myeloma Expansion","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/leu.2013.254","article-title":"Bone Marrow Fibroblasts Parallel Multiple Myeloma Progression in Patients and Mice: In Vitro and In Vivo Studies","volume":"28","author":"Frassanito","year":"2014","journal-title":"Leukemia"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1182\/blood.2021012811","article-title":"Targeting Cancer-Associated Fibroblasts in the Bone Marrow Prevents Resistance to CART-Cell Therapy in Multiple Myeloma","volume":"139","author":"Sakemura","year":"2022","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"9012152","DOI":"10.1155\/2017\/9012152","article-title":"Multiple Myeloma-Derived Exosomes Regulate the Functions of Mesenchymal Stem Cells Partially via Modulating miR-21 and miR-146a","volume":"2017","author":"Cheng","year":"2017","journal-title":"Stem Cells Int."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Simeone, P., Bologna, G., Lanuti, P., Pierdomenico, L., Guagnano, M.T., Pieragostino, D., Del Boccio, P., Vergara, D., Marchisio, M., and Miscia, S. (2020). Extracellular Vesicles as Signaling Mediators and Disease Biomarkers across Biological Barriers. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072514"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.2147\/IJN.S303391","article-title":"Analysis of Amount, Size, Protein Phenotype and Molecular Content of Circulating Extracellular Vesicles Identifies New Biomarkers in Multiple Myeloma","volume":"16","author":"Laurenzana","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Bergantim, R., Peixoto Da Silva, S., Pol\u00f3nia, B., Barbosa, M.A.G., Albergaria, A., Lima, J., Caires, H.R., Guimar\u00e3es, J.E., and Vasconcelos, M.H. (2022). Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients\u2014A Proof of Concept. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213686"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Marchisio, M., Simeone, P., Bologna, G., Ercolino, E., Pierdomenico, L., Pieragostino, D., Ventrella, A., Antonini, F., Del Zotto, G., and Vergara, D. (2020). Flow Cytometry Analysis of Circulating Extracellular Vesicle Subtypes from Fresh Peripheral Blood Samples. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010048"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Manu, D.R., B\u01cela\u015fa, R., Pruteanu, L.-L., Curean, V., Barbu-Tudoran, L., \u015eerban, G.-M., Chinezu, R., and B\u01cela\u015fa, A. (2025). Identification of Distinct Profiles of Glioblastoma through the Immunocapture of Extracellular Vesicles from Patient Plasma. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0315890"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood.2021014749","article-title":"Exosomes in Multiple Myeloma: From Bench to Bedside","volume":"140","author":"Menu","year":"2022","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Xiao, S., Chen, L., Chen, Z., and Li, Q. (2024). Therapeutically Harnessing Tumor Cell-Derived Extracellular Vesicles for Multiple Myeloma: Recent Advances and Future Perspectives. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16111439"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"8166","DOI":"10.1074\/jbc.M114.621383","article-title":"Stabilization of Exosome-Targeting Peptides via Engineered Glycosylation","volume":"290","author":"Hung","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"12277","DOI":"10.1038\/ncomms12277","article-title":"Exosome Engineering for Efficient Intracellular Delivery of Soluble Proteins Using Optically Reversible Protein-Protein Interaction Module","volume":"7","author":"Yim","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1038\/s41467-018-04791-8","article-title":"Efficient RNA Drug Delivery Using Red Blood Cell Extracellular Vesicles","volume":"9","author":"Usman","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1111\/febs.70093","article-title":"Extracellular Vesicles in Multiple Myeloma: Pathogenesis and Therapeutic Application","volume":"292","author":"Wylie","year":"2025","journal-title":"FEBS J."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Chen, T., Moscvin, M., and Bianchi, G. (2020). Exosomes in the Pathogenesis and Treatment of Multiple Myeloma in the Context of the Bone Marrow Microenvironment. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.608815"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s41232-024-00358-x","article-title":"Focusing on Exosomes to Overcome the Existing Bottlenecks of CAR-T Cell Therapy","volume":"44","author":"Zhang","year":"2024","journal-title":"Inflamm. Regen."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"101147","DOI":"10.1016\/j.neo.2025.101147","article-title":"Exosomes in Review: A New Frontier in CAR-T Cell Therapies","volume":"62","author":"Wang","year":"2025","journal-title":"Neoplasia"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Yu, T., Jiao, J.-H., and Wu, M.-F. (2025). CAR-T Cells in the Treatment of Multiple Myeloma: An Encouraging Cell Therapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1499590"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood-2024-206003","article-title":"Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) Trial","volume":"144","author":"Raab","year":"2024","journal-title":"Blood"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"TPS8072","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8072","article-title":"MajesTEC-3: Randomized, Phase 3 Study of Teclistamab plus Daratumumab versus Investigator\u2019s Choice of Daratumumab, Pomalidomide, and Dexamethasone or Daratumumab, Bortezomib, and Dexamethasone in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"40","author":"Mateos","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"TPS8064","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064","article-title":"CAMMA 2: A Phase I\/II Trial Evaluating the Efficacy and Safety of Cevostamab in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) Who Have Triple-Class Refractory Disease and Have Received a Prior Anti-B-Cell Maturation Antigen (BCMA) Agent","volume":"41","author":"Kumar","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen \u00d7 CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"40","author":"Shah","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6276\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:12:25Z","timestamp":1784085145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":166,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27146276"],"URL":"https:\/\/doi.org\/10.3390\/ijms27146276","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}